CG
CGEM.US Cullinan Oncology LLC
- Market cap
- USD 667M
- P/E
- -
- P/B
- 2.35x
- ROE
- -72.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CGEM.US undervalued?
Graham numberThe Graham number of Cullinan Oncology LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cullinan Oncology LLC fundamental analysis
No fundamental analysis for Cullinan Oncology LLC yet.
Cullinan Oncology LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in pa…
Full company profileCullinan Oncology LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cullinan Oncology LLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 18.9M | 18.9M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -43.0K | -70.0K | -62.0K | 18.9M | -93.0K | -310K | -306K | -311K | - |
| Operating Income | -95.4K | -197K | -14.6M | -22.3M | -60.3M | -68.0M | 145M | -191M | -197M | -242M | -218M |
| EBITDA | - | - | -14.5M | -22.2M | -60.3M | -67.9M | -132M | -190M | -167M | -220M | -213M |
| Net Income | -110K | -317K | -14.2M | -20.0M | -50.8M | -65.0M | 111M | -153M | -167M | -220M | -204M |
| EPS | - | - | -18 | -20 | -1.17 | -1.47 | 2.38 | -3.69 | -3.11 | -3.72 | -3.15 |
| Balance Sheet | |||||||||||
| Total Assets | 118.00 | 3.44K | 34.6M | 100M | 215M | 437M | 561M | 484M | 622M | 448M | 323M |
| Total Liabilities | 1.24M | 578K | 55.3M | 140M | 14.4M | 11.8M | 26.1M | 30.3M | 31.5M | 39.6M | 41.3M |
| Shareholders' Equity | -1.24M | -575K | -20.7M | -40.8M | 199M | 425M | 535M | 454M | 590M | 409M | 281M |
| Cash & Short-term Investments | 118.00 | 91.00 | 33.8M | 98.6M | 210M | 290M | 467M | 467M | 399M | 378M | 290M |
| Total Debt | - | - | - | - | - | - | 5.19M | 3.59M | 2.15M | 2.68M | 2.00M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -24.0K | -229K | -13.5M | -20.9M | -29.8M | -43.4M | -127M | -134M | -145M | -176M | -170M |
| Capital Expenditure | 0.00 | 0.00 | 261K | 20.0K | 10.0K | 589K | 1.13M | 208K | 0.00 | 49.0K | 0.00 |
| Free Cash Flow | - | - | -13.8M | -20.9M | -29.8M | -44.0M | -128M | -134M | -145M | -176M | -170M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -25.6% | -15.3% | 20.8% | -33.8% | -28.4% | -53.8% | -72.4% |
| ROA | -92,805.1% | -9,219.9% | -41.0% | -19.9% | -23.7% | -14.9% | 19.8% | -31.6% | -26.9% | -49.0% | -63.1% |
| Net Profit Margin | - | - | - | - | -268.4% | -343.3% | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | - | 0.01x | 0.01x | 0.00x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cullinan Oncology LLC dividends
Cullinan Oncology LLC has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Aug 31, 2009.
Who owns Cullinan Oncology LLC
- Insiders 0.58%
- Institutions 99.42%
- Public & others 0.00%
- Shares outstanding 64.9M
- Free float 48.8M
Top funds holding CGEM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.95M | 3.04% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.53M | 2.37% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.32M | 2.04% | +2.69% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 846K | 1.31% | +26.60% | Sep 2026 |
| T. Rowe Price New Horizons | 826K | 1.28% | -11.03% | Sep 2026 |
| Fidelity Small Cap Index | 663K | 1.03% | +0.29% | Aug 2026 |
| T. Rowe Price Health Sciences | 584K | 0.91% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 571K | 0.89% | 0.00% | Oct 2026 |
| FI Instl US Sm & Md-Cp Cor Eq USD | 505K | 0.78% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 367K | 0.57% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 352K | 0.55% | +1.12% | Sep 2026 |
| Vanguard Explorer Inv | 335K | 0.52% | +10.27% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 319K | 0.50% | +0.27% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 295K | 0.46% | +0.24% | Oct 2026 |
| T. Rowe Price Small-Mid Cap ETF | 256K | 0.40% | -1.04% | Oct 2026 |
| Fidelity Extended Market Index | 250K | 0.39% | -4.56% | Sep 2026 |
| DFA US Micro Cap I | 202K | 0.31% | +2.62% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 201K | 0.31% | -33.34% | Aug 2026 |
| Dimensional US Small Cap ETF | 190K | 0.29% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 183K | 0.28% | 0.00% | Oct 2026 |
Top institutions holding CGEM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| MPM Oncology Impact Management LP | 9.73M | 15.12% | +27.24% | Jun 2026 |
| Lynx1 Capital Management, LP | 8.96M | 13.93% | 0.00% | Jun 2026 |
| Bvf Inc | 5.75M | 8.94% | 0.00% | Jun 2026 |
| BlackRock Inc | 5.23M | 8.13% | +17.59% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.83M | 5.95% | +88.50% | Jun 2026 |
| State Street Corp | 3.67M | 5.70% | +44.20% | Jun 2026 |
| Kynam Capital Management, LP | 3.11M | 4.84% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.61M | 4.06% | +5.28% | Jun 2026 |
| RTW INVESTMENTS, LLC | 2.36M | 3.67% | +38.59% | Jun 2026 |
| Siren, L.L.C. | 1.89M | 2.94% | +58.66% | Jun 2026 |
| Geode Capital Management, LLC | 1.55M | 2.40% | +13.09% | Jun 2026 |
| Blue Owl Capital Holdings LP | 1.54M | 2.39% | -19.37% | Jun 2026 |
| VR Adviser, LLC | 1.38M | 2.14% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.08M | 1.69% | +3.64% | Sep 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.08M | 1.68% | -2.71% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.00M | 1.56% | +119.91% | Jun 2026 |
| Affinity Asset Advisors, LLC | 876K | 1.36% | +12.10% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 739K | 1.15% | +33.70% | Jun 2026 |
| BOONE CAPITAL MANAGEMENT LLC | 704K | 1.09% | 0.00% | Jun 2026 |
| Elmind Capital LP | 690K | 1.07% | +30.19% | Jun 2026 |
Cullinan Oncology LLC company profile
- Company name
- Cullinan Oncology LLC
- Ticker
- CGEM.US
- Exchange
- USA Stocks
- Listed since
- Jan 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Fiscal year end
- December
- Address
- One Main Street, Cambridge, MA, United States, 02142
- Phone
- 617 410 4650
- Website
- cullinantherapeutics.com
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Oncology LLC management
10- Mr. Nadim Ahmed M.S.President, CEO & Director · born 1968
- Ms. Mary Kay Fenton CPAChief Financial Officer · born 1964
- Dr. Jeffrey Jones M.B.A., M.D., M.P.H.Chief Medical Officer · born 1971
- Dr. Patrick A. Baeuerle Ph.D.Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board · born 1958
- Dr. Jennifer Michaelson Ph.D.Chief Scientific Officer · born 1967
- Nicholas SmithHead of Investor Relations
- Ms. Jacquelyn L. Sumer J.D.Chief Legal Officer, Chief Compliance Officer & Corporate Secretary · born 1978
- Mr. Steve AndreChief Human Resources Officer
- Dr. Corinne Savill Ph.D.Chief Business Officer · born 1959
- Ms. Rose WeldonSenior Vice President of Corporate Affairs